T. Rowe Price Associates
RARE icon

T. Rowe Price Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

T. Rowe Price Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.8M Sell
804,109
-750,257
-48% -$16.9M ﹤0.01% 1087
2025
Q4 		$35.8M Sell
1,554,366
-755,808
-33% -$24.9M ﹤0.01% 912
2025
Q3 		$69.5M Sell
2,310,174
-576,094
-20% -$17.3M 0.01% 696
2025
Q2 		$105M Sell
2,886,268
-332,674
-10% -$12M 0.01% 561
2025
Q1 		$117M Buy
3,218,942
+706,519
+28% +$29.4M 0.01% 522
2024
Q4 		$106M Sell
2,512,423
-556,231
-18% -$27.6M 0.01% 558
2024
Q3 		$170M Buy
3,068,654
+76,696
+3% +$3.91M 0.02% 464
2024
Q2 		$123M Sell
2,991,958
-576,915
-16% -$24.6M 0.01% 501
2024
Q1 		$167M Buy
3,568,873
+120,175
+3% +$5.67M 0.02% 455
2023
Q4 		$165M Buy
3,448,698
+288,538
+9% +$11.2M 0.02% 443
2023
Q3 		$113M Sell
3,160,160
-454,832
-13% -$18M 0.02% 493
2023
Q2 		$167M Buy
3,614,992
+71,231
+2% +$3.3M 0.02% 425
2023
Q1 		$142M Sell
3,543,761
-552,627
-13% -$23.7M 0.02% 449
2022
Q4 		$190M Sell
4,096,388
-660,568
-14% -$26M 0.03% 388
2022
Q3 		$197M Sell
4,756,956
-6,023,200
-56% -$310M 0.03% 364
2022
Q2 		$643M Sell
10,780,156
-1,104,630
-9% -$68M 0.08% 239
2022
Q1 		$863M Buy
11,884,786
+359,697
+3% +$25M 0.09% 229
2021
Q4 		$969M Buy
11,525,089
+66,043
+0.6% +$5.37M 0.09% 231
2021
Q3 		$1.03B Buy
11,459,046
+459,832
+4% +$41.6M 0.1% 216
2021
Q2 		$1.05B Buy
10,999,214
+327,428
+3% +$34.1M 0.1% 220
2021
Q1 		$1.22B Buy
10,671,786
+1,201,294
+13% +$164M 0.12% 188
2020
Q4 		$1.31B Buy
9,470,492
+1,121,763
+13% +$133M 0.13% 165
2020
Q3 		$686M Buy
8,348,729
+682,112
+9% +$56.5M 0.08% 254
2020
Q2 		$600M Buy
7,666,617
+2,957,795
+63% +$196M 0.08% 265
2020
Q1 		$209M Buy
4,708,822
+217,053
+5% +$11.3M 0.03% 398
2019
Q4 		$192M Buy
4,491,769
+36,184
+0.8% +$1.49M 0.02% 490
2019
Q3 		$191M Sell
4,455,585
-156,354
-3% -$8.49M 0.03% 458
2019
Q2 		$293M Buy
4,611,939
+1,110,316
+32% +$70.7M 0.04% 377
2019
Q1 		$243M Buy
3,501,623
+771,242
+28% +$44.1M 0.04% 415
2018
Q4 		$119M Sell
2,730,381
-47,648
-2% -$2.6M 0.02% 565
2018
Q3 		$212M Sell
2,778,029
-18,363
-0.7% -$1.49M 0.03% 473
2018
Q2 		$215M Buy
2,796,392
+544,691
+24% +$35.2M 0.03% 453
2018
Q1 		$115M Buy
2,251,701
+130,846
+6% +$6.59M 0.02% 608
2017
Q4 		$98.4M Buy
2,120,855
+496,135
+31% +$24.3M 0.02% 647
2017
Q3 		$86.5M Sell
1,624,720
-136,869
-8% -$8.11M 0.01% 665
2017
Q2 		$109M Buy
1,761,589
+90,765
+5% +$5.47M 0.02% 570
2017
Q1 		$113M Buy
1,670,824
+1,317
+0.1% +$100K 0.02% 564
2016
Q4 		$117M Sell
1,669,507
-158,100
-9% -$11.2M 0.02% 551
2016
Q3 		$130M Buy
1,827,607
+235,630
+15% +$15M 0.03% 517
2016
Q2 		$77.9M Buy
1,591,977
+242,340
+18% +$15.7M 0.02% 646
2016
Q1 		$85.4M Sell
1,349,637
-1,750
-0.1% -$115K 0.02% 596
2015
Q4 		$152M Sell
1,351,387
-7,568
-0.6% -$757K 0.03% 457
2015
Q3 		$131M Buy
1,358,955
+179,815
+15% +$20.6M 0.03% 509
2015
Q2 		$121M Sell
1,179,140
-66,700
-5% -$5.18M 0.02% 551
2015
Q1 		$77.4M Sell
1,245,840
-70,300
-5% -$3.9M 0.02% 690
2014
Q4 		$57.8M Sell
1,316,140
-750
-0.1% -$34.4K 0.01% 797
2014
Q3 		$74.5M Buy
1,316,890
+63,611
+5% +$3.2M 0.02% 692
2014
Q2 		$53.7M Sell
1,253,279
-137,700
-10% -$5.67M 0.01% 842
2014
Q1 		$65.2M Buy
+1,390,979
New +$71.6M 0.01% 773

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates's RARE Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Ultragenyx Pharmaceutical (RARE) stake by 48% in Q1 2026, selling an estimated $16.9M and leaving 804,109 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

T. Rowe Price Associates first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $1.31B in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • T. Rowe Price Associates held 804,109 shares of Ultragenyx Pharmaceutical worth $16.8M as of Q1 2026.
  • T. Rowe Price Associates sold 750,257 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $16.9M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1087 holding.
  • T. Rowe Price Associates first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • T. Rowe Price Associates's Ultragenyx Pharmaceutical position peaked at $1.31B in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.